Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug trial aims to control rare autoimmune blood disease

NCT ID NCT05073458

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

Summary

This study tested whether a medication called parsaclisib could help people with warm autoimmune hemolytic anemia (wAIHA), a rare condition where the immune system attacks red blood cells. The trial compared parsaclisib against a placebo (inactive pill) in 13 participants over 24 weeks to see if it could safely raise hemoglobin levels and reduce fatigue. The goal was to find a new treatment option for people who haven't responded well to other therapies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigative Site AT001

    Vienna, 01090, Austria

  • Investigative Site AT002

    Salzburg CET, A-5020, Austria

  • Investigative Site BE001

    La Louvière, 07100, Belgium

  • Investigative Site BE002

    Liège, 04000, Belgium

  • Investigative Site CA001

    Edmonton, Alberta, T6G 2P4, Canada

  • Investigative Site DE001

    Essen, 45147, Germany

  • Investigative Site DE002

    Ulm, 89081, Germany

  • Investigative Site ES001

    Barcelona, 08036, Spain

  • Investigative Site ES002

    Valencia, 46026, Spain

  • Investigative Site ES003

    Madrid, 28006, Spain

  • Investigative Site ES004

    Tarragona, 43005, Spain

  • Investigative Site ES005

    Murcia, 30008, Spain

  • Investigative Site ES006

    Badalona, 08916, Spain

  • Investigative Site FR001

    Paris, 75015, France

  • Investigative Site FR002

    Lille, 59037, France

  • Investigative Site FR003

    Marseille, 13285, France

  • Investigative Site GB002

    Glasgow, G4 0SF, United Kingdom

  • Investigative Site GB003

    Norwich, NR4 7UY, United Kingdom

  • Investigative Site GB004

    Plymouth, PL6 8DH, United Kingdom

  • Investigative Site GB005

    Reading, RG1 5AN, United Kingdom

  • Investigative Site GB006

    London, W12 0HS, United Kingdom

  • Investigative Site IL001

    Nahariya, 2210001, Israel

  • Investigative Site IL002

    Haifa, 31096, Israel

  • Investigative Site IT001

    Novara, 28100, Italy

  • Investigative Site IT002

    Milan, 20122, Italy

  • Investigative Site IT003

    Florence, 50134, Italy

  • Investigative Site IT004

    Pavia, 27100, Italy

  • Investigative Site IT005

    Trieste, 34125, Italy

  • Investigative Site IT006

    Rome, 00168, Italy

  • Investigative Site JP001

    Suita-shi, 565-0871, Japan

  • Investigative Site JP002

    Okayama, 701-0192, Japan

  • Investigative Site JP003

    Tokyo, 141-8625, Japan

  • Investigative Site JP004

    Isehara, 259-1193, Japan

  • Investigative Site JP005

    Saitama, 350-0495, Japan

  • Investigative Site JP006

    Nagoya, 467-8602, Japan

  • Investigative Site JP007

    Sendai, 980-8574, Japan

  • Investigative Site JP008

    Fukuoka, 807-8556, Japan

  • Investigative Site JP009

    Okayama, 700-8557, Japan

  • Investigative Site JP010

    Osakasayama-shi, 589-8511, Japan

  • Investigative Site NL001

    Rotterdam, 3015CA, Netherlands

  • Investigative Site PL001

    Legnica, 59220, Poland

  • Investigative Site PL002

    Wroclaw, 53-439, Poland

  • Investigative Site PL003

    Nowy Sącz, 33-300, Poland

  • Investigative Site PL004

    Wałbrzych, 58-309, Poland

  • Investigative Site PL005

    Opole, 45-372, Poland

  • Investigative Site PL006

    Lodz, 93-510, Poland

  • Investigative Site US001

    Knoxville, Tennessee, 37920, United States

  • Investigative Site US002

    The Bronx, New York, 10467, United States

  • Investigative Site US003

    Greenville, North Carolina, 27858, United States

  • Investigative Site US004

    Whittier, California, 90603, United States

  • Investigative Site US005

    Los Angeles, California, 90089, United States

  • Investigative Site US006

    Miami, Florida, 33165, United States

  • Investigative Site US007

    The Bronx, New York, 10461, United States

  • Investigative Site US009

    Canton, Ohio, 44718, United States

  • Investigative Site US010

    Easton, Pennsylvania, 18045, United States

  • Investigative Site US012

    Indianapolis, Indiana, 46260, United States

Conditions

Explore the condition pages connected to this study.

WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA)